The Accelerated Access Collaborative (AAC) has announced that Roche Diagnostics tests for suspected pre-eclampsia and heart attack have been recognised as ‘transformative’ and have been selected among only seven Rapid Uptake Products for the NHS.
Following the Government’s response to the Accelerated Access Review, the AAC are bringing together senior leadership from the Government, the NHS and the life sciences industry to drive the uptake and adoption of innovation in the NHS, identifying and supporting the innovations that will be most transformative for patients.
Both diagnostic tests have been previously assessed and recommended by the National Institute for Health and Care Excellence (NICE) for use in clinical practice. The Roche Elecsys immunoassay sFlt-1/PlGF ratio test, used with standard clinical assessment and subsequent clinical follow-up, is recommended to help rule-out pre-eclampsia in women presenting with suspected pre-eclampsia between 20 weeks and 34 weeks plus 6 days of gestation.
The Elecsys Troponin T high?sensitive assay is recommended for the early rule out of non?ST?segment?elevation myocardial infarction (NSTEMI) or heart attack in people presenting to an emergency department with chest pain and suspected acute coronary syndrome.
Both are simple blood tests that can help clinicians quickly decide on the right course of action for patients and their families. The tests also have the potential to alleviate pressure on NHS resources by supporting clinical decision making and focusing efforts where they are most needed.
